METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill aims to outsmart Drug-Resistant prostate cancer
Disease control Recruiting nowThis early-phase study tests a new oral medication, (R)-9bMS, in about 18-30 men with metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to standard hormone therapy). The drug works by blocking a protein called ACK1, which may help shri…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control
Last updated May 26, 2026 06:10 UTC
-
New combo aims to boost radiation therapy for advanced prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can make the radiation work better for men with advanced prostate cancer that has stopped responding to other treatments. About 30 participants will receive the combinat…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New targeted radiation trial hopes to slow resistant prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug, 177Lu-PSMA-617, in 51 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug seeks out prostate cancer cells and damages their DNA to slow tumor growth. The goal is to see if this treatment can de…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Triple-Drug attack aims to halt bone metastases in prostate cancer
Disease control Recruiting nowThis study is for men with advanced prostate cancer that no longer responds to hormone therapy and has spread to bones or lymph nodes. It tests whether adding the experimental drug M3814 and/or the immunotherapy avelumab to the standard radioactive drug radium-223 can better cont…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New imaging test could sharpen view of prostate cancer
Diagnosis Recruiting nowThis study tests a new type of PET scan (18F-DCFPyL-PSMA) to see how well it shows prostate cancer in 30 men with advanced disease who are already scheduled for a targeted radiation therapy. The goal is to compare this scan with the standard one to see if it detects cancer spots …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 26, 2026 06:04 UTC